Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Por um escritor misterioso
Descrição
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Immunogenicity of SARS-CoV-2 vaccines in patients with cancer: Trends in Molecular Medicine
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis - ScienceDirect
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases, Inflammation and Regeneration
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
de
por adulto (o preço varia de acordo com o tamanho do grupo)
